TrialBlood advances2026
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialBlood advances2026
Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.